ShiraTronics 在 B 轮融资中筹集了 $66M 用于 FDA 批准的偏头痛治疗设备试验。 ShiraTronics raises $66M in Series B funding for FDA-approved migraine therapy device trial.

希拉特罗尼克公司已筹集了6600万美元的B轮资金,以支持其FDA批准的RELIEV-CM2试验,用于偏头痛治疗系统,针对治疗耐药慢性偏头痛患者. ShiraTronics has raised $66 million in Series B funding to support its FDA-approved RELIEV-CM2 trial for the Migraine Therapy System, targeting treatment-resistant chronic migraine patients. 这种最小侵入性装置将电脉冲输送到与偏头痛有关的神经区域,目的是改善病人的治疗结果。 This minimally invasive device, which delivers electrical pulses to nerve areas associated with migraines, aims to improve patient outcomes. 资金还将有助于获得FDA的市场准备批准,并将治疗推向商业领域,为目前治疗不满意的患者提供更多选择. The funding will also help secure FDA premarket approval and launch the therapy commercially, enhancing options for patients dissatisfied with current treatments.